We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Pacific Biosciences of California (PACB - Free Report) to post quarterly loss of $0.20 per share in its upcoming report, which indicates a year-over-year increase of 25.9%. Revenues are expected to be $41.9 million, down 24.8% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Pacific Biosciences metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Product- Instrument' at $17.48 million. The estimate indicates a change of -49.6% from the prior-year quarter.
The consensus estimate for 'Revenue- Service and other' stands at $4.23 million. The estimate points to a change of +2.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Product- Consumable' will likely reach $19.31 million. The estimate suggests a change of +14.5% year over year.
Pacific Biosciences shares have witnessed a change of +41.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.4% move. With a Zacks Rank #3 (Hold), PACB is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Wall Street analysts expect Pacific Biosciences of California (PACB - Free Report) to post quarterly loss of $0.20 per share in its upcoming report, which indicates a year-over-year increase of 25.9%. Revenues are expected to be $41.9 million, down 24.8% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Pacific Biosciences metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenue- Product- Instrument' at $17.48 million. The estimate indicates a change of -49.6% from the prior-year quarter.
The consensus estimate for 'Revenue- Service and other' stands at $4.23 million. The estimate points to a change of +2.5% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Product- Consumable' will likely reach $19.31 million. The estimate suggests a change of +14.5% year over year.
View all Key Company Metrics for Pacific Biosciences here>>>
Pacific Biosciences shares have witnessed a change of +41.9% in the past month, in contrast to the Zacks S&P 500 composite's +0.4% move. With a Zacks Rank #3 (Hold), PACB is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>